ATC Group: C01AA08 Metildigoxin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01AA08 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01A Cardiac glycosides
4 C01AA Digitalis glycosides
5 C01AA08 Metildigoxin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.2 mg
PAREN - Parenteral 0.2 mg

Active ingredients in C01AA08

Active Ingredient Description
Metildigoxin

Metildigoxin, a methyl derivative of digoxin, is a cardiac glycoside a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia.

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Germany (DE)

Japan (JP)

Poland (PL)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.